<- Go Home
AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Market Cap
$21.6M
Volume
1.1M
Cash and Equivalents
$3.0M
EBITDA
-$16.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.45
52 Week Low
$0.46
Dividend
N/A
Price / Book Value
-0.18
Price / Earnings
-0.21
Price / Tangible Book Value
-0.18
Enterprise Value
$54.3M
Enterprise Value / EBITDA
-3.41
Operating Income
-$16.3M
Return on Equity
93.84%
Return on Assets
-234.17
Cash and Short Term Investments
$3.0M
Debt
$35.7M
Equity
-$55.0M
Revenue
N/A
Unlevered FCF
-$11.0M
Sector
Biotechnology
Category
N/A